Thailand ERT Endometrial Receptivity Test: Target Population and Clinical Value Analysis
AI Summary
ERT (Endometrial Receptivity Test) determines whether the endometrium is in the "window of implantation" suitable for embryo implantation by analyzing the expression levels of specific genes in endometrial tissue. This test is suitable for patients with recurrent implantation failure or suspected window displacement. Some reproductive centers in Thailand offer ERT/ERA testing services, typically requiring an endometrial biopsy during a complete cycle, with results available in about 2-3 weeks. Not all implantation failures require ERT; doctors make a comprehensive judgment based on embryo quality, previous transfer attempts, and endometrial conditions. The results can guide subsequent adjustments to transfer timing but cannot guarantee implantation success, nor can they replace the investigation of embryo or uterine cavity factors.
Opening: Real Consultation Scenario
"Doctor, I've had two transfers in my home country, both with good quality embryos, but neither implanted. An agent suggested I go to Thailand for ERT, saying it can check when my endometrium is most suitable for transfer. How effective is this technology really?"
This was a question from a 39-year-old patient in our clinic last week. In the past six months, similar consultations have become increasingly common in reproductive clinics. With the spread of information about assisted reproductive technology in Thailand, ERT (Endometrial Receptivity Test) has attracted more and more patients with recurrent implantation failure. But is this technology suitable for everyone? What exactly does it involve? What problems can the results solve?
The following content explains the principles, applicable scenarios, procedural details, and limitations of ERT technology from a clinical reproductive medicine perspective.
Module Combination: A + C + I + J + G + H + L + Q
What is ERT Technology? How Do Doctors Evaluate Its Value?
ERT (Endometrial Receptivity Test), also known as ERA (Endometrial Receptivity Array), is a detection method based on gene expression profiling. It determines whether the endometrium is in the "receptive phase"—the few days when an embryo can successfully implant—by analyzing the expression levels of approximately 248 genes related to receptivity in endometrial tissue.
In a normal menstrual cycle, the endometrium is only "open" to an embryo for a specific few days (called the "window of implantation," or WOI). If the window is advanced, delayed, or shortened, the timing of embryo transfer may be out of sync with the endometrial state, leading to implantation failure.
Core Clinical Perspective: ERT is a targeted diagnostic tool, not a routine screening test. Its value lies in helping patients whose "embryos appear normal but fail to implant" identify endometrial factors. Among the recurrent implantation failure (RIF) population, approximately 20% to 30% have a displaced window of implantation. ERT can identify this group and guide adjustments to transfer timing.
However, it is important to note that ERT cannot solve all implantation problems. Embryo chromosomal abnormalities, intrauterine adhesions, chronic endometritis, and immune factors can also lead to transfer failure. Before recommending ERT, doctors must first rule out these more common factors.
Who is Suitable for ERT?
- Recurrent Implantation Failure (RIF): Typically defined as failure to implant after ≥2 transfers of good quality embryos.
- Single failed transfer of a good quality blastocyst that was euploid after PGT screening.
- Few previous transfers, but endometrial morphology, thickness, or blood flow patterns suggest possible window abnormalities.
- Age ≥38 years with thin endometrium or an unstable implantation window.
Who is Not Suitable for ERT?
- Patients undergoing their first transfer or those who have not yet ruled out embryo factors.
- Presence of untreated uterine pathology (e.g., polyps, adhesions, endometritis).
- Failure clearly due to embryo chromosomal abnormalities (e.g., PGT results showing aneuploidy).
- Persistent endometrial thickness <6mm with poor response to hormone replacement therapy.
- Active infection or uterine bleeding.
Standard Procedure for ERT Testing in Thailand
In Thailand, ERT testing is typically performed at reproductive centers with molecular biology laboratories, such as Jetanin, BNH Hospital, and Bangkok Hospital. The entire process consists of five steps:
| Step | Details | Key Notes |
|---|---|---|
| 1. Cycle Preparation | The doctor selects a hormone replacement therapy (HRT) cycle or a natural cycle for endometrial preparation. | HRT cycles are more controllable and are the most common protocol in Thailand. Medication includes oral estradiol, vaginal gel, or patches. |
| 2. Endometrial Biopsy | A small sample of endometrial tissue is taken using a disposable biopsy catheter at the same time point as the planned transfer (HRT cycle day 5-6, or LH+7 in a natural cycle). | The procedure is performed in an outpatient setting, requires no anesthesia, and takes about 1-2 minutes. Some patients may experience mild cramping. |
| 3. Sample Shipping | The tissue sample is placed in a special preservation solution and sent to a partner molecular laboratory for RNA extraction and gene expression analysis. | Some centers send samples to laboratories in the US or Europe, while others complete the testing locally in Thailand. |
| 4. Result Interpretation | Results are received in approximately 2-3 weeks, indicating: Receptive, Pre-receptive, or Post-receptive, and suggesting the optimal transfer time. | The report must be interpreted by a reproductive specialist in conjunction with the patient's clinical situation; self-interpretation is not recommended. |
| 5. Protocol Adjustment | Based on the results, the medication duration or transfer day in the subsequent cycle is adjusted. | If the window is displaced, the doctor will adjust the number of days of progesterone administration or switch to a different progesterone preparation. |
Timeline: How Long Does It Take from Testing to Transfer?
The ERT test itself does not change the overall length of an IVF cycle, but it requires advance planning. Here is a typical timeline:
- Cycle 1 (Preparation + Biopsy): Approximately 10-14 days (for HRT cycle) or determined by ovulation timing in a natural cycle.
- Waiting for Results: 2-3 weeks after the biopsy.
- Cycle 2 (Adjusted Transfer): Based on ERT results, the transfer is performed at the adjusted time in the next cycle, taking about 10-14 days.
From the start of preparation to the completion of the transfer, the total time is approximately 2 to 2.5 months. For older patients or those with diminished ovarian reserve, doctors may suggest considering ERT concurrently with embryo culture to avoid the time loss of an extra cycle.
Easily Overlooked Details
In clinical practice, the following details are often overlooked but directly affect the accuracy of ERT:
- The biopsy timing must match the transfer timing. If the ERT biopsy is performed on P+5 of an HRT cycle, the subsequent transfer must also be on P+5; otherwise, the results are not meaningful.
- The endometrial preparation protocol must be consistent between the test cycle and the transfer cycle. If oral estradiol was used in the biopsy cycle, the same medication and dosage should be used in the transfer cycle; it should not be changed arbitrarily.
- Impact of the biopsy on the endometrium. Some patients worry that the biopsy will damage the endometrium. In reality, a single micro-biopsy causes minimal damage and typically heals completely within 1-2 cycles. However, repeated biopsies in consecutive cycles require careful attention to intervals.
- Laboratory differences. Different laboratories use different gene testing platforms and algorithms, which can lead to variations in results. It is advisable to choose a laboratory with proper accreditation and clinical validation data.
Common Pitfalls
Myth 1: "Having an ERT guarantees implantation." — ERT addresses the question of "when to transfer," not "embryo quality" or "the inherent receptivity of the endometrium." If the embryo has chromosomal abnormalities or there are immune issues, ERT cannot solve them.
Myth 2: "Everyone should have ERT to optimize their endometrium." — For patients undergoing their first transfer with good quality embryos, the clinical benefit of ERT is not clearly established. Unnecessary testing adds financial and cycle burden.
Myth 3: "A normal ERT result means the endometrium is fine." — ERT only evaluates the window of implantation. It does not assess endometrial morphology, blood flow, microbiome, or immune status. A normal result does not guarantee the endometrium is entirely healthy.
Myth 4: "All reproductive centers in Thailand offer the same ERT service." — There are differences in biopsy experience, reference laboratories, and result interpretation capabilities among centers. It is advisable to choose a center with a clear ERT protocol and a track record of cases.
How to Understand the ERT Test Report
ERT reports typically present results in one of three states:
| Report Status | Meaning | Clinical Recommendation |
|---|---|---|
| Receptive | The endometrium is in a state suitable for implantation at the time of biopsy, and the window aligns with expectations. | Proceed with the transfer as originally planned; no timing adjustment needed. |
| Pre-receptive | The endometrium has not yet entered the window, suggesting the window may be delayed. | Extend the duration of progesterone administration, delaying the transfer by 1-2 days. |
| Post-receptive | The window has passed, and the endometrium is no longer suitable for implantation, suggesting the window may be advanced. | Shorten the duration of progesterone administration, advancing the transfer. |
Some reports also provide a specific "optimal transfer time recommendation," such as "transfer on day 6 of progesterone administration" or "transfer on LH+7.5." The doctor will create an individualized plan based on the report and the patient's previous cycle characteristics.
Frequently Asked Questions
The biopsy causes brief cramping, similar to menstrual pain, lasting about 1-2 minutes. A single micro-biopsy has a minimal overall impact on the endometrium. Clinical observations show that the endometrium can recover after resting for 1-2 cycles. However, repeated biopsies in consecutive cycles require careful evaluation.
The test fee typically ranges from $3,000 to $5,000 USD, depending on the partner laboratory and center pricing. Including cycle preparation, ultrasound monitoring, biopsy procedure, and medication, the total cost is approximately $5,000 to $8,000 USD. Some centers offer package prices. This test is self-funded and is currently not covered by Thai health insurance.
The gene expression analysis technology used in ERT has been clinically validated. In the recurrent implantation failure population, the detection rate for window displacement is about 20% to 30%. However, any test has limitations: in rare cases, results may be inconclusive due to insufficient cellular components in the endometrial sample, gene expression fluctuations, or laboratory errors. It is advisable to choose a laboratory with accumulated clinical data.
This situation suggests the cause of implantation failure may not be related to the window of implantation. The following areas need investigation: embryo chromosomal euploidy status (PGT-A), uterine cavity microenvironment (chronic endometritis, dysbiosis), immune factors (NK cells, thyroid antibodies), and thrombophilia. It is recommended to conduct a comprehensive failure analysis with your reproductive doctor rather than repeating the ERT.
You will need: ① Complete records of previous transfers (including embryo grades, transfer dates, and endometrial preparation protocols); ② A recent hysteroscopy report (to rule out polyps, adhesions, etc.); ③ Baseline endocrine tests (e.g., AMH, FSH, LH); ④ A passport (for medical record creation and cycle registration). It is advisable to communicate with the center's medical coordinator in advance to confirm the testing process and cycle plan.
Differences in ERT Application Across Populations
| Population Characteristic | ERT Application Considerations | Notes |
|---|---|---|
| Age < 35 | Probability of window displacement is relatively low (about 10% to 15%). Consider ERT only after ≥2 failed transfers of good quality embryos. | Prioritize investigating embryo and uterine cavity factors. |
| Age 35-40 | Probability of window displacement increases (about 20% to 25%), especially in those with thin endometrium or irregular cycles. | Discuss the necessity of ERT with your doctor after the 1st or 2nd failed transfer. |
| Age > 40 | Probability of window displacement can reach over 30%, but the rate of embryo chromosomal abnormalities also increases simultaneously. ERT should be evaluated in conjunction with PGT-A. | It is recommended to complete embryo genetic screening first before deciding on ERT. |
| Recurrent Implantation Failure (RIF) | The clinical value of ERT is most clearly established in the RIF population, with approximately 25% to 30% showing window displacement that guides adjustments. | Simultaneously investigate chronic endometritis, immune factors, etc. |
Local Characteristics of ERT Testing in Thailand
Reproductive centers in Thailand have several characteristics in their application of ERT technology:
- Primarily International Partner Laboratories: Some centers send samples to reference laboratories in the US or Europe (e.g., Igenomix) for analysis. The testing cycle takes about 2-3 weeks, and results are reported in English, requiring interpretation by the center's doctors.
- Process Convenience: Thai centers typically have Chinese coordinators to assist patients with cycle appointments, biopsy scheduling, and result communication, reducing language barriers.
- Cost Transparency: Most centers list the ERT test fee separately from the cycle fee, allowing patients to choose whether to undergo testing in the current cycle. Some centers offer "ERT + PGT" combined packages.
- Variation in Doctor Experience: There are differences in how doctors interpret ERT results and adjust protocols. It is advisable to choose a reproductive specialist with extensive clinical experience in ERT cases.
How to Determine if You Need ERT
Before recommending ERT, doctors typically complete the following investigations:
- Confirm embryo quality: Has PGT screening been performed? Is it a good quality blastocyst?
- Confirm uterine cavity environment: Has a hysteroscopy been performed? Are there polyps, adhesions, or endometritis?
- Confirm previous cycles: Was the endometrial thickness, morphology, and blood flow adequate on the transfer day?
- Confirm immune status: Are there any diagnosed autoimmune diseases or thrombophilic conditions?
If the above factors have been ruled out or treated, but recurrent implantation failure persists, then ERT is a reasonable next diagnostic step. Conversely, if embryo or uterine cavity factors are still unclear, undergoing ERT blindly may waste time and money.
Risk Reminder:
ERT is an invasive procedure. Although the risk is low, there is a possibility of bleeding, infection, or endometrial injury after the biopsy, with an incidence rate of approximately 0.5% to 1%. The test results cannot 100% reflect the state of all cycles; the window of implantation may vary due to cycle fluctuations, medication changes, or endocrine status. Furthermore, ERT cannot replace embryo genetic screening, hysteroscopy, or immune evaluation. It is recommended to make decisions under the guidance of a reproductive doctor, based on your individual clinical situation, and avoid viewing ERT as a "universal solution." All assisted reproductive technologies carry uncertainties, and managing expectations rationally is an important part of the treatment process.
— Reproductive Medicine Knowledge Base · Patient Education —
